Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBIT (2016 - 2025)

Historic EBIT for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$27.4 million.

  • UroGen Pharma's EBIT fell 5609.01% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.4 million, marking a year-over-year decrease of 5932.31%. This contributed to the annual value of -$96.8 million for FY2024, which is 4767.76% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's EBIT is -$27.4 million, which was down 5609.01% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EBIT registered a high of -$13.5 million during Q3 2023, and its lowest value of -$41.4 million during Q2 2025.
  • Over the past 5 years, UroGen Pharma's median EBIT value was -$22.0 million (recorded in 2023), while the average stood at -$23.1 million.
  • As far as peak fluctuations go, UroGen Pharma's EBIT surged by 2822.96% in 2021, and later crashed by 8932.17% in 2024.
  • Over the past 5 years, UroGen Pharma's EBIT (Quarter) stood at -$19.9 million in 2021, then fell by 1.84% to -$20.3 million in 2022, then grew by 27.97% to -$14.6 million in 2023, then tumbled by 89.32% to -$27.7 million in 2024, then rose by 0.98% to -$27.4 million in 2025.
  • Its last three reported values are -$27.4 million in Q3 2025, -$41.4 million for Q2 2025, and -$36.9 million during Q1 2025.